IP Library Granted Patent US 11,433,025
Granted Patent B2
US 11,433,025 · App. 15/999,088 · Granted Sep 6, 2022

Oil foamable carriers and formulations

Inventors: Dov Tamarkin (Macabim, IL); Helena Shifrin (Rehovot, IL); Rita Keynan (Rehovot, IL); Enbal Ziv (Gedera, IL); Tal Berman (Rishon le Ziyyon, IL); David Schuz (Gimzu, IL); Elana Gazal (Rehovot, IL)
Assignee: Vyne Therapeutics Inc.
A61K9/12A61K8/046A61K9/0014A61K9/122A61K31/20A61K31/355A61K31/522A61K31/59A61K31/65A61K31/7056A61K45/06A61K47/06A61K47/14A61K47/24A61K47/34A61K47/44Y10S514/871Y10S514/945
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,433,025
App. No.
15/999,088
Granted
Sep 6, 2022
Kind
B2
Abstract

A waterless foamable pharmaceutical composition suitable for external administration is disclosed. The composition includes a foamable carrier least one liquefied or compressed gas propellant. The foamable carrier includes at least one liquid oil; at least one silicone and at least one least one stabilizing agent; wherein the stabilizing agent selected from the group consisting of about 0.01% to about 25% by weight of at least one surface-active agent alone or on combination with a foam adjuvant; and about 0% to about 5% by weight of at least one polymeric agent alone or on combination with a foam adjuvant; and mixtures thereof. Pharmaceutical compositions comprising active agents, methods for their preparation, propellants suitable for use with the carriers and uses thereof are further described.

Claims (22)

1. An essentially waterless foam composition comprising:

(a) a liquid oil;

(b) a modulating agent;

(c) a foam stabilizing agent comprising at least two surface-active agents;

(d) an emollient comprising a solid wax and/or solid oil; and

(e) a silicone;

wherein the surface-active agents are not sorbitan fatty acid esters;

wherein the composition does not contain a polymeric agent; and

wherein the foam does not comprise a pharmaceutical or cosmetic active agent.

2. The foam composition of claim 1 , wherein the liquid oil is about 60% to about 95% by weight of the composition.

3. The foam composition of claim 1 , wherein the liquid oil is selected from the group consisting of a mineral oil, a MCT oil, a liquid paraffin, a vegetable oil, an essential oil, an organic oil, a lipid, or a mixture of two or more thereof.

4. The foam composition of claim 1 , wherein the liquid oil is a mixture of heavy mineral oil and light mineral oil having a weight ratio from about 1:5 to about 25:1.

5. The foam composition of claim 1 , wherein the amount of the at least two surface-active agents is between about 0.2% and about 8% by weight of the composition.

6. The foam composition of claim 1 , wherein the at least two surface-active agents comprise between about 1% and about 6% by weight of the composition.

7. The foam composition of claim 1 , wherein the modulating agent is between about 0.1% to about 10% by weight of the composition.

8. The foam composition of claim 1 , wherein the modulating agent is between about 1% to about 5% by weight of the composition.

9. The foam composition of claim 1 , wherein at least one of the surface-active agents comprises a fatty acid ester.

10. The foam composition of claim 9 , wherein the fatty acid ester is selected from the group consisting of a monoglyceride, diglyceride, or triglyceride, or a mixture of any two or more thereof, wherein the side chain of the monoglyceride, diglyceride, or triglyceride is a saturated hydrocarbon.

11. The foam composition of claim 9 , wherein the fatty acid ester comprises glyceryl monostearate.

12. The foam composition of claim 1 , wherein the solid wax or solid oil comprises a solid paraffin, a hydrogenated oil, a hydrogenated emollient, palmitic acid, or a mixture of any two or more thereof.

13. The foam composition of claim 1 , wherein the emollient comprises a solid wax and a solid oil.

14. The foam composition of claim 13 , wherein the emollient further comprises a cocoglyceride, PPG 15 stearyl alcohol, octyldodecanol, isopropyl myristate, diisopropyl adipate, cetearyl octanoate isohexadecanol, diisopropyl adipate, or a mixture of any two or more thereof.

Assignments (11)
SECURITY INTEREST Recorded Dec 28, 2023
From: JOURNEY MEDICAL CORPORATION; JG PHARMA, INC.
To: SWK FUNDING LLC
Reel/Frame 066157/0079 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2022
From: VYNE THERAPEUTICS INC.; VYNE PHARMACEUTICALS INC.
To: JOURNEY MEDICAL CORPORATION
Reel/Frame 058925/0568 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2021
From: VYNE THERAPEUTICS INC.
To: VYNE PHARMACEUTICALS INC.
Reel/Frame 058463/0167 →
RELEASE OF SECURITY INTEREST Recorded Sep 20, 2021
From: PERCEPTIVE CREDIT HOLDINGS II, LP
To: VYNE PHARMACEUTICALS LTD. (F/K/A FOAMIX PHARMACEUTICALS LTD.)
Reel/Frame 057544/0138 →
RELEASE OF SECURITY INTEREST Recorded Sep 20, 2021
From: PERCEPTIVE CREDIT HOLDINGS II, LP
To: VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.)
Reel/Frame 057544/0708 →
PATENT SECURITY AGREEMENT Recorded Feb 17, 2021
From: VYNE THERAPEUTICS INC.
To: PERCEPTIVE CREDIT HOLDINGS II, LP
Reel/Frame 055326/0009 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2021
From: VYNE PHARMACEUTICALS LTD.
To: VYNE THERAPEUTICS INC.
Reel/Frame 055215/0298 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 19, 2020
From: TAMARKIN, DOV; SHIFRIN, HELENA; KEYNAN, RITA; ZIV, ENBAL; BERMAN, TAL; SCHUZ, DAVID; GAZAL, ELANA
To: FOAMIX LTD.
Reel/Frame 054421/0714 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 19, 2020
From: FOAMIX LTD.
To: FOAMIX PHARMACEUTICALS LTD.
Reel/Frame 054482/0694 →
CHANGE OF NAME Recorded Nov 4, 2020
From: FOAMIX PHARMACEUTICALS LTD.
To: VYNE PHARMACEUTICALS LTD.
Reel/Frame 054306/0387 →
PATENT SECURITY AGREEMENT Recorded Jul 30, 2019
From: FOAMIX PHARMACEUTICALS LTD
To: PERCEPTIVE CREDIT HOLDINGS II, LP
Reel/Frame 049912/0045 →
Continuity (7)
Continuation 15349240 · Nov 11, 2016
Continuation 14504942 · Oct 2, 2014
Continuation 12795213 · Jun 7, 2010
Continuation PCTIB2008003939 · Dec 8, 2008
Provisional Application 61103500 · Oct 7, 2008
Provisional Application 61012414 · Dec 7, 2007
Related Publication 20190091149A1 · Mar 28, 2019
Cited By (1)
US 12,661,407